Linked Life Data

19745699

Source:http://linkedlifedata.com/resource/pubmed/id/19745699

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2009-11-25
pubmed:abstractText
Recent observations indicate that some sessile serrated adenomas (SSAs) have aberrant beta-catenin nuclear labeling, implicating the Wnt pathway in the molecular progression of SSAs to colorectal carcinoma. We sought to expand upon this finding by characterizing beta-catenin expression in the full spectrum of serrated colorectal polyps, and correlating these findings with the genetic status of BRAF, KRAS and CTNNB1. Immunolabeling for beta-catenin confirmed the presence of abnormal nuclear accumulation in SSAs, with 35/54 (67%) SSAs showing nuclear labeling compared with 0/12 hyperplastic polyps. Abnormal nuclear labeling was also identified in 4/11 (36%) traditional serrated adenomas (TSAs) (P=0.00001). When SSAs were further analyzed with respect to the presence or absence of conventional epithelial dysplasia, nuclear beta-catenin labeling was seen in 8/27 (29%) SSAs without dysplasia (SSA) but in 27/27 (100%) of SSAs with dysplasia (P=0.000001). Sequencing of genomic DNA extracted from a subset of hyperplastic polyps, SSAs, SSAs with dysplasia, TSAs and tubular adenomas failed to identify any CTNNB1 mutations to account for abnormal beta-catenin nuclear labeling. However, abnormal nuclear labeling always occurred in the setting of a BRAF V600E mutation, indicating aberrant nuclear labeling occurs on a background of BRAF activation. Of interest, all 6 TSAs contained a KRAS mutation confirming that SSAs and TSAs are genetically distinct entities. These findings validate previous reports implicating activation of the Wnt signaling pathway in SSAs, and further indicate that Wnt pathway activation plays a role in the neoplastic progression of SSAs and TSAs to colonic carcinoma by mechanisms independent of CTNNB1 mutation.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1532-0979
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
33
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1823-32
pubmed:dateRevised
2011-6-13
pubmed:meshHeading
pubmed-meshheading:19745699-Adenoma, pubmed-meshheading:19745699-Aged, pubmed-meshheading:19745699-Base Sequence, pubmed-meshheading:19745699-Cell Nucleus, pubmed-meshheading:19745699-Cell Transformation, Neoplastic, pubmed-meshheading:19745699-Colonic Polyps, pubmed-meshheading:19745699-Colorectal Neoplasms, pubmed-meshheading:19745699-DNA Mutational Analysis, pubmed-meshheading:19745699-Female, pubmed-meshheading:19745699-Humans, pubmed-meshheading:19745699-Hyperplasia, pubmed-meshheading:19745699-Immunohistochemistry, pubmed-meshheading:19745699-Male, pubmed-meshheading:19745699-Middle Aged, pubmed-meshheading:19745699-Molecular Sequence Data, pubmed-meshheading:19745699-Mutation, pubmed-meshheading:19745699-Proto-Oncogene Proteins, pubmed-meshheading:19745699-Proto-Oncogene Proteins B-raf, pubmed-meshheading:19745699-Transcriptional Activation, pubmed-meshheading:19745699-beta Catenin, pubmed-meshheading:19745699-ras Proteins
pubmed:year
2009
pubmed:articleTitle
Beta-catenin nuclear labeling is a common feature of sessile serrated adenomas and correlates with early neoplastic progression after BRAF activation.
pubmed:affiliation
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural